SuppreMol to develop monoclonal antibody to treat rheumatoid arthritis
08:26 EDT 26 Jul 2012 | Avakado
Autoimmune disease specialist company SuppreMol GmbH has formed a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanised anti-IL-3 monoclonal antibody for early diagnosis and treatment of rheumatoid arthritis (RA..
Original Article: SuppreMol to develop monoclonal antibody to treat rheumatoid arthritis
More From BioPortfolio on "SuppreMol to develop monoclonal antibody to treat rheumatoid arthritis"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
